Bristol Myers Squibb: Cheap Valuation Confronts Looming Patent Cliff and Policy Risks

What happened

The Motley Fool article highlights that Bristol Myers Squibb trades below 10 times forward earnings due to impending patent protections on two blockbuster drugs, raising concerns about revenue replacement. The DeepValue master report rates BMY a WAIT with an attractive entry at $55 and a trim level above $70, reflecting near-term policy pressures on Eliquis and an expected step-change in Revlimid erosion beginning January 31, 2026. Management's 2026 guidance of $46.0–47.5B revenue and $6.05–6.35 non-GAAP EPS hinges on Eliquis achieving 10–15% growth while maintaining gross margin in the 69–70% range. The Growth Portfolio grew 17% in FY25, but the market's low multiple indicates skepticism that new drugs can fully offset legacy declines. Investors should watch Q1-Q2 2026 results for evidence of margin stability and pipeline execution before adding positions.

Implication

If BMY meets 2026 guidance and delivers positive pipeline readouts in 2H26, the stock could re-rate toward $65–75; conversely, failure to hold margins or setbacks in late-stage trials could push the stock toward the bear case of $52. The current price of $60.46 offers modest upside to the base case but lacks a sufficient margin of safety for aggressive accumulation, so investors should await observable proof points before committing capital.

Thesis delta

The article reiterates familiar patent cliff concerns but does not introduce new information beyond the master report's existing analysis. The WAIT rating remains appropriate, with the same key checkpoints: Eliquis volume defense without gross-to-net deterioration and Revlimid erosion acceleration post-Jan 2026. No change to thesis; we continue to emphasize waiting for Q1-Q2 2026 confirmation before adjusting exposure.